Inhalis Therapeutics SA reaches a milestone with the filing of the patent application.

2023-08-21 10:02:06

Lugano, Switzerland, June 12 /PRNewswire/ Inhalis Therapeutics SA, a pioneering, privately held company specializing in advanced inhalation therapies for life-threatening diseases, presents a significant step forward with the filing of a new patent application for INHAL-101, its lead compound. This strategic move strengthens the company’s positioning and enriches its intellectual property portfolio.

dr Silvia Panigone, Managing Director of Inhalis Therapeutics, expressed her excitement and stated, “Reaching this important milestone is a moment of great pride for Inhalis.” Our dedicated team has worked tirelessly to develop INHAL-101, a unique small molecule PI3K/mTOR/BRD4 trispecific inhibitor. This breakthrough formulation leverages proprietary mSAS® supercritical fluid technology and demonstrates compelling potential to address the complex challenges of idiopathic pulmonary fibrosis (IPF). By selectively inhibiting the IPF-driven pathogenic elements through a single inhalable drug with excellent safety potential, INHAL-101 offers the opportunity to unleash its full pharmacological power as an effective and well-tolerated drug. This latest patent filing strengthens our competitive position and creates additional value for Inhalis. We remain true to our purpose and are dedicated above all to the people affected by IPF who will benefit from our tireless commitment.”

About Inhalis Therapeutics SA

Inhalis Therapeutics SA is committed to developing breakthrough inhaled treatments for life-threatening diseases. Solid science and industry-leading delivery technology are combined with an experienced management team to discover and develop new inhaled treatments for idiopathic pulmonary fibrosis and other diseases. The lead compound, INHAL-101, a breakthrough solution for IPF, is expected to enter clinical testing in Q4 2024. The Company’s line of products also includes INHAL-102, which is targeted for the treatment of lung cancer, as well as additional compounds in late stage preclinical efficacy studies for oncology, fibrotic diseases and lung infections.

Related Articles:  UNOS core demand of reducing bureaucracy was screwed up by the business association | UNOS

For more information, please contact:

Dr Silvia Panigone, EMBA

Manager

Inhalis Therapeutics SA

Tel.: +41 78 89 89 644

E-Mail: silvia.panigone@inhalis.com

Logo –

View original content:

1692612789
#Inhalis #Therapeutics #reaches #milestone #filing #patent #application

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.